Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research2,831

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research2,831

Filters

Status

Recruiting1,209
Not yet recruiting11
Enrolling by invitation20
Active, not recruiting553
Completed895
Terminated143

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Not reported1,641
Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 4

Investigator

Gail J Roboz49
Parag Goyal36
Harini Sarva33
Shari Lipner30
Manish A Shah28

Show all 50Show fewer

Department

Medicine1,340
Pediatrics239
Obstetrics and Gynecology150
Radiology137
Population Health Sciences121

Show all 26Show fewer

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Show all 50Show fewer

Intervention type

Drug807
Other202
Device190
Biological157
Procedure127
Behavioral83

Sponsor type

WCM (investigator-initiated)1,383
Industry853
Other academic408
NIH107
Unknown41
Cooperative group35

Start date

Has results posted347

Showing 2741–2760 of 2,831 studiesSort:

CompletedInterventional · Phase 4NCT05544734 ↗
Analysis of Hydrocodone Compared to Acetaminophen and Ibuprofen for Post-nail Procedure Analgesia
Shari LipnerPI
Intervention
Drug: Hydrocodone 5Mg/Acetaminophen 325Mg Tab · Drug: Acetaminophen 1000mg · Drug: Ibuprofen 400 mg
Dates
Nov 2022 – May 2023· Results posted
Sponsor
Weill Medical College of Cornell University
Nail DiseasesNail Abnormality

Filters

Status

Recruiting1,209
Not yet recruiting11
Enrolling by invitation20
Active, not recruiting553
Completed895
Terminated143

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Not reported1,641
Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 4

Investigator

Gail J Roboz49
Parag Goyal36
Harini Sarva33
Shari Lipner30
Manish A Shah28

Show all 50Show fewer

Department

Medicine1,340
Pediatrics239
Obstetrics and Gynecology150
Radiology137
Population Health Sciences121

Show all 26Show fewer

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Show all 50Show fewer

Intervention type

Drug807
Other202
Device190
Biological157
Procedure127
Behavioral83

Sponsor type

WCM (investigator-initiated)1,383
Industry853
Other academic408
NIH107
Unknown41
Cooperative group35

Start date

Has results posted347

Showing 2741–2760 of 2,831 studiesSort:

CompletedInterventional · Phase 4NCT05544734 ↗
Analysis of Hydrocodone Compared to Acetaminophen and Ibuprofen for Post-nail Procedure Analgesia
Shari LipnerPI
Intervention
Drug: Hydrocodone 5Mg/Acetaminophen 325Mg Tab · Drug: Acetaminophen 1000mg · Drug: Ibuprofen 400 mg
Dates
Nov 2022 – May 2023· Results posted
Sponsor
Weill Medical College of Cornell University
Nail DiseasesNail Abnormality

Robert J. Kaner

Alexander Ja-Ho Chou15

Catherine Butkus Small14

Jia Ruan14

Anna Podolanczuk13

Eleni Andreopoulou13

Silvia Chiara Formenti13

Darshana M Dadhania11

Otolaryngology Head and Neck Surgery65

Neurological Surgery59

Cardiothoracic Surgery57

Emergency Medicine48

Anesthesiology46

Pathology and Laboratory Medicine39

Radiation Oncology37

Urology36

Rehabilitation Medicine25

Ophthalmology17

Orthopaedic Surgery11

Systems and Computational Biomedicine11

Genetic Medicine3

Pharmacology3

Biochemistry and Biophysics2

Brain and Mind Research2

Library2

Neoplasms32

Colitis, Ulcerative29

Atrial Fibrillation27

Carcinoma, Non-Small-Cell Lung27

Crohn Disease27

Recurrence27

COVID-1926

Myelodysplastic Syndromes26

Parkinson Disease24

Neoplasm Metastasis23

Obesity23

Colorectal Neoplasms19

HIV Infections19

Hematologic Neoplasms19

Cardiovascular Diseases18

Depression18

Non-alcoholic Fatty Liver Disease16

Overweight15

Lung Neoplasms14

Melanoma14

Cognitive Dysfunction13

Idiopathic Pulmonary Fibrosis13

Inflammatory Bowel Diseases13

Alzheimer Disease12

Leukemia12

Leukemia, Lymphocytic, Chronic, B-Cell12

Lymphoma, Non-Hodgkin12

Primary Myelofibrosis12

Coronary Artery Disease11

Hypertension11

Hypertension, Pulmonary11

Lung Diseases, Interstitial11

Myeloproliferative Disorders11

Pulmonary Arterial Hypertension11

Stroke11

Chronic Pain10

Hemophilia A10

Leukemia, Myelomonocytic, Chronic10

Lymphoma, Follicular10

Lymphoma, Large B-Cell, Diffuse10

Urinary Bladder Neoplasms10

Burkitt Lymphoma9

Fibrosis9

Liver Diseases9

Carcinoma, Renal Cell8

Radiation

Diagnostic test31

Dietary supplement14

Combination product11

Genetic7

Other federal

CompletedInterventional · Phase 2NCT05551273 ↗

Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Kristen MarksPI

Intervention: Drug: Selgantolimod · Drug: Placebo
Dates: May 2023 – Oct 2025
Sponsor: National Institute of Allergy & Infectious Diseases

Hepatitis BHIV Infections

TerminatedInterventional · Phase 1NCT05556616 ↗

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: Modakafusp alfa · Drug: Lenalidomide · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab · Drug: Pomalidomide
Dates: Jan 2023 – Jun 2024· Results posted
Sponsor: Takeda Development Center Americas, Inc.

Multiple Myeloma

CompletedInterventional · Not applicableNCT05565534 ↗

Optimizing Delivery of Diabetes Management During Breast Cancer Care

Laura PinheiroPI

Intervention: Behavioral: Nurse-practitioner led intervention
Dates: Feb 2023 – Jul 2025· Results posted
Sponsor: Weill Medical College of Cornell University

Breast CancerPreDiabetesType 2 Diabetes

CompletedInterventional · Phase 2NCT05571293 ↗

Novel Exploratory Study to Test Combination of Botensilimab and Balstilimab Immunotherapy in Resectable Colorectal Cancer Patients

Manish A ShahPI

Intervention: Drug: Botensilimab · Drug: Balstilimab
Dates: Mar 2023 – Nov 2024· Results posted
Sponsor: Weill Medical College of Cornell University

Colorectal Neoplasms

TerminatedInterventional · Phase 4NCT05582681 ↗

HCV Test and Treat Utilizing Simplified HCV Patient Education

Robert S. BrownPI

Intervention: Diagnostic test: Cepheid POC HCV Viremia (RNA) test · Other: HCV education from a health care provider · Drug: Glecaprevir and Pibrentasvir
Dates: Nov 2022 – Nov 2024
Sponsor: Weill Medical College of Cornell University

Hepatitis C

CompletedInterventional · Phase 3NCT05587309 ↗

A Phase 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Felice H Schnoll-SussmanPI

Intervention: Drug: BLI5100 · Drug: PPI Control
Dates: Oct 2022 – Jun 2025
Sponsor: Braintree Laboratories, INC

Erosive Esophagitis

CompletedInterventional · Phase 3NCT05587322 ↗

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

Felice H Schnoll-SussmanPI

Intervention: Drug: BLI5100 · Drug: Placebo
Dates: Sep 2022 – Oct 2023
Sponsor: Braintree Laboratories, INC

Non-erosive Reflux Disease

CompletedInterventional · Phase 2NCT05595369 ↗

RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Matthew William McCarthyPI

Intervention: Drug: Experimental: Paxlovid 25 day dosing · Drug: Experimental: Paxlovid 15 day dosing · Drug: Placebo Comparator: Control
Dates: Jul 2023 – Aug 2024· Results posted
Sponsor: Duke University

Long COVIDLong Covid19

CompletedInterventional · Phase 1/2NCT05603312 ↗

A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease

Harini SarvaPI

Intervention: Genetic: AAV-GAD Low Dose · Genetic: AAV-GAD High Dose · Procedure: Sham Surgery
Dates: Oct 2022 – Sep 2024· Results posted
Sponsor: MeiraGTx, LLC

Parkinson's Disease

TerminatedInterventional · Phase 3NCT05605093 ↗

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor

Matthew William McCarthyPIAlexander DrelickPI

Intervention: Drug: Shionogi Protease Inhibitor (S-217622) · Drug: placebo
Dates: Dec 2022 – Oct 2025· Results posted
Sponsor: University of Minnesota

COVID-19

CompletedInterventional · Phase 3NCT05614063 ↗

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Padmaja KandulaPI

Intervention: Drug: XEN1101 · Drug: Placebo
Dates: Nov 2022 – Jan 2026
Sponsor: Xenon Pharmaceuticals Inc.

Focal Onset Seizures

CompletedInterventional · Phase 2NCT05616013 ↗

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Louis J AronnePI

Intervention: Biological: Bimagrumab · Drug: Semaglutide · Other: Placebo
Dates: Nov 2022 – May 2024· Results posted
Sponsor: Versanis Bio

ObesityObeseOverweight or Obesity

TerminatedInterventional · Phase 1/2NCT05617040 ↗

A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Cora SternbergPI

Intervention: Biological: ChAdOx1-PCAQ · Biological: MVA-PCAQ
Dates: Jan 2023 – Feb 2025· Results posted
Sponsor: Vaccitech (UK) Ltd.

Prostate Cancer

TerminatedInterventional · Phase 1NCT05618366 ↗

Phase I Trial of Tazemetostat in Combination With Venetoclax in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

Erin MulveyPI

Intervention: Drug: Venetoclax · Drug: Tazemetostat
Dates: Jun 2023 – Feb 2026
Sponsor: Weill Medical College of Cornell University

Lymphoma, Non-HodgkinDiffuse Large B Cell LymphomaFollicular Lymphoma

CompletedInterventional · Phase 2NCT05630183 ↗

A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)

Allyson J OceanPI

Intervention: Drug: Botensilimab · Drug: Gemcitabine · Drug: Nab-paclitaxel
Dates: Mar 2023 – Jan 2026
Sponsor: Agenus Inc

Metastatic Pancreatic Ductal Adenocarcinoma

CompletedInterventional · Phase 2NCT05630885 ↗

A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Marshall J. GlesbyPI

Intervention: Drug: CVC 150 mg · Drug: CVC 300 mg · Other: Placebo for CVC 150 mg · Other: Placebo for CVC 300 mg
Dates: May 2023 – Jun 2024· Results posted
Sponsor: National Institute of Allergy & Infectious Diseases

HIV-1-infectionElevated Cardiovascular Risk

TerminatedInterventional · Phase 3NCT05636176 ↗

Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Parag GoyalPI

Intervention: Drug: Ziltivekimab · Drug: Placebo
Dates: May 2023 – Sep 2026
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

Heart Failure

TerminatedInterventional · Phase 2NCT05643638 ↗

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease

Tsiporah B ShorePI

Intervention: Biological: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) · Biological: Placebo · Drug: Corticosteroids
Dates: Mar 2024 – Mar 2026
Sponsor: Cynata Therapeutics

Graft Versus Host Disease, Acute

TerminatedInterventional · Phase 3NCT05665595 ↗

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)

Anna C PavlickPI

Intervention: Biological: Pembrolizumab/Vibostolimab · Biological: Pembrolizumab
Dates: Jan 2023 – Mar 2024· Results posted
Sponsor: Merck & Co., Inc.

Melanoma

‹ Prev 1 2 3 4 5…137 138 139 140 141 142 Next ›